Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial

BACKGROUND: STARDUST is a phase 3b randomized controlled trial comparing two ustekinumab treatment strategies in patients with Crohn's disease (CD): treat‐to‐target (T2T) versus standard of care (SoC). OBJECTIVE: We investigated the effect of a T2T or SoC ustekinumab treatment strategy on healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Panés, Julian, Vermeire, Séverine, D'Haens, Geert R., Danese, Silvio, Magro, Fernando, Nazar, Maciej, Le Bars, Manuela, Lahaye, Marjolein, Ni, Lioudmila, Bravatà, Ivana, Gaya, Daniel R., Peyrin‐Biroulet, Laurent, Dignass, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256988/
https://www.ncbi.nlm.nih.gov/pubmed/37139642
http://dx.doi.org/10.1002/ueg2.12384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256988/
https://www.ncbi.nlm.nih.gov/pubmed/37139642
http://dx.doi.org/10.1002/ueg2.12384

Ejemplares similares